Skip to Main content Skip to Navigation
Journal articles

Compatibility at amino acid position 98 of MICB reduces the incidence of graft-versus host disease in conjunction with the CMV status

Raphaël Carapito 1, 2, 3, 4, 5 Ismaïl Aouadi 1, 2, 3, 4 Angelique Pichot 1, 2, 3, 4 Perrine Spinnhirny 1, 2, 3, 4 Aurore Morlon 2, 6 Irina Kotova 2, 6 Cécile Macquin 1, 2, 3, 4 Véronique Rolli 1, 2, 3, 4 Anne Cesbron 2, 7, 8 Katia Gagne 9, 2, 7 Machteld Oudshoorn 10, 11 Bronno van der Holt 12 Myriam Labalette 13, 14 Eric Spierings 15 Christophe Picard 16 Pascale Loiseau 2, 8, 17 Ryad Tamouza 2, 17 Antoine Toubert 2, 8, 17 Anne Parissiadis 8, 18 Valérie Dubois 19 Catherine Paillard 1, 2, 8, 20 Myriam Maumy-Bertrand 21 Frédéric Bertrand 21 Peter von Dem Borne 11 Jürgen Kuball 15 Mauricette Michallet 8, 22 Bruno Lioure 8, 20 Régis Peffault de Latour 2, 8, 23 Didier Blaise 8, 24 Jan J. Cornelissen 25 Ibrahim Yakoub Agha 8, 14 Frans H.J. Claas 11 Philippe Moreau 8, 26 Dominique Charron 1, 2, 17 Mohamad Mohty 8, 27, 28, 29 Yasuo Morishima 30 Gérard Socié 2, 8, 20 Seiamak Bahram 1, 2, 3, 4, 5
1 Inserm U1109 - Equipe Plate-forme GENOMAX
Immuno-Rhumatologie Moléculaire, Fédération Hospitalo-Universitaire OMICARE, FMTS - Fédération de Médecine Translationnelle de Strasbourg
2 LabEx Transplantex [Strasbourg]
3 FJ-HLA - INSERM Franco-Japanese Nextgen HLA Laboratory [Strasbourg]
4 INSERM Franco-Japanese Nextgen HLA Laboratory[Nagano]
5 Plateau Technique de Biologie - Pôle de Biologie - Laboratoire d’Immunologie [Nouvel Hôpital Civil, Strasbourg]
6 BIOMICA SA [Strasbourg]
7 Etablissement Français du Sang [Nantes]
8 Hôpital Edouard Herriot [CHU - HCL]
9 CRCINA - Département INCIT - Equipe 1 - Immunobiology of Human αβ and γδ T cells and Immunotherapeutic Applications
CRCINA - Centre de recherche de Cancérologie et d'Immunologie / Nantes - Angers
10 Europdonor operated by Matchis Foundation [Leiden]
11 Leiden University Medical Center (LUMC)
12 Erasmus MC Cancer Institute, Rotterdam
13 Laboratoire d'Immunologie [Lille]
14 LIRIC - Lille Inflammation Research International Center
15 University Medical Center [Utrecht]
16 ADES - Anthropologie bio-culturelle, Droit, Ethique et Santé
17 EMily (UMR_S_1160 / U1160) - Ecotaxie, microenvironnement et développement lymphocytaire
18 EFS - alsace strasbourg - Etablissement Français du Sang - Grand Est
19 EFS - Etablissement français du sang - Auvergne-Rhône-Alpes
20 Les Hôpitaux Universitaires de Strasbourg (HUS)
21 IRMA - Institut de Recherche Mathématique Avancée
22 HCL - Hospices Civils de Lyon
23 Hôpital Saint-Louis
24 Institut Paoli-Calmettes
25 Erasmus MC - Erasmus University Medical Center [Rotterdam]
26 Hôpital Hôtel-Dieu [Paris]
27 AP-HP - Hôpital Saint-Antoine
28 Université Pierre & marie Curie
29 CR Saint-Antoine - Centre de Recherche Saint-Antoine
30 Aichi Cancer Center Research Institute
Abstract : Graft-versus-host disease (GVHD) and cytomegalovirus (CMV)-related complications are leading causes of mortality after unrelated-donor hematopoietic cell transplantation (UD-HCT). The non-conventional MHC class I gene MICB, alike MICA, encodes a stress-induced polymorphic NKG2D ligand. However, unlike MICA, MICB interacts with the CMV-encoded UL16, which sequestrates MICB intracellularly, leading to immune evasion. Here, we retrospectively analyzed the impact of mismatches in MICB amino acid position 98 (MICB98), a key polymorphic residue involved in UL16 binding, in 943 UD-HCT pairs who were allele-matched at HLA-A, -B, -C, -DRB1, -DQB1 and MICA loci. HLA-DP typing was further available. MICB98 mismatches were significantly associated with an increased incidence of acute (grade II-IV: HR, 1.20; 95% CI, 1.15 to 1.24; P < 0.001; grade III-IV: HR, 2.28; 95% CI, 1.56 to 3.34; P < 0.001) and chronic GVHD (HR, 1.21; 95% CI, 1.10 to 1.33; P < 0.001). MICB98 matching significantly reduced the effect of CMV status on overall mortality from a hazard ratio of 1.77 to 1.16. MICB98 mismatches showed a GVHD-independent association with a higher incidence of CMV infection/reactivation (HR, 1.84; 95% CI, 1.34 to 2.51; P < 0.001). Hence selecting a MICB98-matched donor significantly reduces the GVHD incidence and lowers the impact of CMV status on overall survival.
Complete list of metadatas

Cited literature [37 references]  Display  Hide  Download
https://www.hal.inserm.fr/inserm-02545513
Contributor : Elizabeth Bernardo <>
Submitted on : Friday, April 17, 2020 - 10:49:10 AM
Last modification on : Monday, April 20, 2020 - 12:07:37 PM

File

 Restricted access
To satisfy the distribution rights of the publisher, the document is embargoed until : 2020-10-14

Please log in to resquest access to the document

Identifiers

Collections

HCL | IRMA | RIIP | HEH | U938 | ANTHROPO-MARSEILLE | CRCINA | UNIV-NANTES | UNIV-LILLE | UNIV-AMU | SORBONNE-UNIVERSITE | SU-MEDECINE | UNIV-ANGERS | CNRS | SITE-ALSACE | UP-SANTE | RIIP_LILLE

Citation

Raphaël Carapito, Ismaïl Aouadi, Angelique Pichot, Perrine Spinnhirny, Aurore Morlon, et al.. Compatibility at amino acid position 98 of MICB reduces the incidence of graft-versus host disease in conjunction with the CMV status. Bone Marrow Transplantation, Nature Publishing Group, 2020, 15, Online ahead of print. ⟨10.1038/s41409-020-0886-5⟩. ⟨inserm-02545513⟩

Export

BibTeX TEI DC DCterms EndNote

Share

Metrics

Record views

92

Contact

Informations

CCSD